Qiagen

QGEN

Market cap $10.3B

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025. Press release date / time: Tuesday, November 4, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, November 5, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?

Qiagen N.V. (NYSE:QGEN ) Bank of America Global Healthcare Conference 2025 September 25, 2025 5:45 AM EDT Company Participants John Gilardi - VP & Head of Corporate Communications Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division Thanks for joining us.

QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has achieved CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel that sets a new benchmark in the diagnosis of central nervous system (CNS) infections. The QIAstat-Dx system now offers CE-IVDR certified panels for respiratory, gastrointestinal and CNS infections that help clinicians d.

Qiagen N.V. (NYSE:QGEN ) Baird Global Healthcare Conference 2025 September 10, 2025 1:25 PM EDT Company Participants Roland Sackers - CFO, MD & Member of Management Board John Gilardi - VP & Head of Corporate Communications Presentation Unknown Analyst Diagnostics here at Baird.

Qiagen N.V. (NYSE:QGEN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Roland Sackers - CFO, MD & Member of Management Board John Gilardi - VP & Head of Corporate Communications Conference Call Participants Aisyah Noor - Morgan Stanley, Research Division Presentation Aisyah Noor Equity Analyst So thanks for joining us today.

QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide. The new system, which received clearance from the U.S. Food and Drug Administration (FDA), is designed to meet the needs of hospitals and reference laboratories seeking highly automat.

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the final terms of the new senior, unsecur.